Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of “Hold” from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned a consensus recommendation of “Hold” from the eleven analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $40.8889.

Several research firms recently weighed in on AGIO. JPMorgan Chase & Co. cut their price target on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday. Citigroup boosted their price target on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. The Goldman Sachs Group boosted their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Truist Financial cut their price target on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Friday, March 27th.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock opened at $29.46 on Friday. Agios Pharmaceuticals has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock has a market cap of $1.75 billion, a PE ratio of -4.06 and a beta of 0.59. The firm’s 50-day simple moving average is $29.34 and its 200 day simple moving average is $28.49.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The business had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $13.30 million. The firm’s revenue for the quarter was up 137.7% on a year-over-year basis. As a group, analysts predict that Agios Pharmaceuticals will post -6.2 EPS for the current fiscal year.

Insider Activity

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,141 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total value of $109,024.11. Following the sale, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James William Burns sold 3,280 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $113,848.80. Following the completion of the sale, the insider directly owned 49,306 shares in the company, valued at approximately $1,711,411.26. This represents a 6.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 12,623 shares of company stock valued at $438,144 in the last three months. 5.40% of the stock is owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AGIO. T. Rowe Price Investment Management Inc. bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $25,000. Assetmark Inc. raised its position in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 362 shares during the period. NewEdge Advisors LLC bought a new stake in Agios Pharmaceuticals in the first quarter worth about $40,000. Caitong International Asset Management Co. Ltd bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $49,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $72,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.